Pfizer

Ginkgo Bioworks has announced a collaboration with Pfizer focused on the discovery of RNA-based drug candidates.   In the collaboration, Pfizer will leverage Ginkgo’s proprietary RNA technology to advance the discovery and development of novel RNA molecules across priority research areas. Ginkgo will receive an upfront payment and is eligible to receive research fees and development […]

As the second quarter of 2023 draws to a close, DDW’s Megan Thomas reviews key updates and results from three top pharmaceutical companies. Business updates   Pfizer reported second quarter 2023 revenues totalling $12.7 billion, a decrease of $15.0 billion, or 54%, compared to the prior year quarter, reflecting an operational decline of $14.7 billion, or […]

Approval has been granted by the Medicines and Healthcare products Regulatory Agency (MHRA) for an adapted Pfizer/BioNTech Covid-19 vaccine that targets the Omicron XBB 1.5 subvariant. The new version of Comirnaty was found to meet the UK regulator’s standards of safety, quality and effectiveness and has been approved for use in individuals from six months […]

Arvinas and Pfizer UK have been awarded a UK Innovation Passport for vepdegestrant (ARV-471), an investigational PROTAC ER (estrogen receptor) degrader. It is intended for the treatment of patients with oestrogen receptor (ER)+/ human epidermal growth factor receptor (HER)2- locally-advanced breast cancer or metastatic breast cancer. The Innovation Passport is the entry point for the […]

The US Food and Drug Administration (FDA) has approved the first vaccine for pregnant individuals to prevent respiratory syncytial virus (RSV) in infants. Pfizer’s Abrysvo (Respiratory Syncytial Virus Vaccine) was approved for use at 32-36 weeks gestational age of pregnancy to prevent lower respiratory tract disease (LRTD) and severe LRTD caused by RSV in infants […]

The US Food and Drug Administration (FDA) has granted accelerated approval to Pfizer’s Elrexfio (elranatamab-bcmm) for the treatment of adult patients with relapsed or refractory multiple myeloma (RRMM). The drug is approved in patients who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal […]

It is believed that new Covid-19 vaccines developed by Pfizer/BioNTech, Moderna and Novavax will be effective against the fast-spreading EG.5 strain. EG.5 or ‘Eris’ has been found in more than 50 countries. It is the most common and fastest growing Covid-19 subvariant in the US, estimated to be responsible for around 17% of current Covid-19 […]

This is the latest episode of the free DDW narrated podcast, “A business case for drug discovery”, which covers three articles written for Volume 23, Issue 3 – Summer 2022 of DDW. They are called “A deal in the making”, “Why project management holds the key to efficient drug development”, and “Transcending expectations for cell & […]

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates.  Regulatory approvals and industry guidelines are key to the continued development and discovery of drugs, which is a common theme throughout this week’s […]

News round-up for 5-9 June by DDW Multimedia Editor Megan Thomas.  Regulatory approvals and industry guidelines are key to the continued development and discovery of drugs, which is a common theme throughout this week’s news highlights, including an FDA approval for Pfizer, a NICE recommendation for AstraZeneca UK, and an update to the HER2 Breast […]

An FDA approval for Pfizer’s Abrysvo respiratory syncytial virus (RSV) vaccine is likely to threaten GSK’s current hold on the market, according to GlobalData.  GSK received approval by the European Commision (EC) for its vaccine Arexvy, which targets the prevention of lower respiratory tract infections (LRTI) caused by RSV in adults 60 years of age […]

The US Food and Drug Administration (FDA) has approved Pfizer’s bivalent respiratory syncytial virus (RSV) prefusion F (RSVpreF) vaccine Abrysvo in individuals 60 years and older. Abrysvo is unadjuvanted and composed of two preF proteins selected to optimise protection against RSV A and B strains and was observed to be safe and effective. “A vaccine […]

Merck has bought the exclusive worldwide rights to develop, manufacture and commercialise anti PD-L1 antibody Bavencio (avelumab) from Pfizer. Merck will take full control of the global commercialisation of Bavencio through its affiliate Ares Trading. The transaction has also ended a long-term collaboration between Merck and Pfizer. The current profit share will be replaced by […]

One the UK’s largest science and innovation parks has revealed plans to double in size as it celebrates its ten-year anniversary. Discovery Park, based near Sandwich in Kent, marked the milestone by announcing its plans for the next ten years, which include the creation of a national centre of excellence for neuroscience, alongside life sciences, […]

Pfizer has extended its multi-year partnership with CytoReason to use CytoReason’s artificial intelligence (AI) technology for Pfizer’s drug development programs.   Pfizer will make a $20 million equity investment, have options to license CytoReason’s platform and disease models, and fund supplementary project support. This deal which has the potential to be worth up to $110 million over the […]

Biotechnology company Moderna has filed a patent infringement lawsuit against Pfizer and BioNTech in relation to the use of its messenger RNA (mRNA) technology and Pfizer and BioNTech’s Covid-19 Comirnaty vaccine. The lawsuits, which were made in the United States and Germany, state that Pfizer and BioNTech’s Covid-19 vaccine Comirnaty infringes Moderna’s patents for its […]